Amgen’s Nplate Maintains Platelet Counts for More Than Five Years in Adults with Chronic ITP Amgen Inc. announced the ultimate results from a 5-year open-label extension study investigating the long-term efficacy and security of Nplate in adult chronic immune thrombocytopenic purpura boldenone acetate more info . Chronic ITP can be a significant autoimmune disorder characterized by low platelet counts in the blood , which can result in serious bleeding occasions. The complete data, provided as an oral presentation at the 52nd Annual Meeting and Exposition of the American Culture of Hematology , demonstrated that Nplate securely and effectively managed platelet counts in the significant majority of patients for the duration of the analysis .
‘Amgen and Roche will work closely to ensure a seamless transition of the business, marketing authorizations, and most importantly, product source to the doctors and patients that rely on these important medicines,’ said Anthony C. Hooper, executive vice president, Global Commercial Functions of Amgen. ‘Amgen is certainly very happy to have the chance to prevent individuals getting myelosuppressive chemotherapy from developing febrile neutropenia in extra markets around the world.’ Amgen has grown to be the world’s largest independent biotechnology organization reaching millions of patients around the world. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to sufferers who need them.